Navigation Links
ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Date:8/19/2007

t rate of 38% after 8 weeks, including partial responses and stable disease, for patients with recurrent DIPG in this study represents a unique observation in these end-stage patients and has generated considerable interest.

More than half of the high-grade brain cancers or gliomas over-express epidermal growth factor receptor (EGFR) and for the most advanced brain cancers, glioblastoma multiforme (GBM), the level of expression is even higher. A study involving 29 adults with newly diagnosed high-grade gliomas, including both anaplastic astrocytomas (AA) and GBM, who were treated with surgery, external beam radiotherapy and nimotuzumab showed that the treatment was well tolerated, the median survival time was 17.5 months for the GBM patients, and has not yet been reached for the AA patients.

Nimotuzumab

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). To date nimotuzumab has been administered to approximately 900 patients in more than a dozen clinical trials and on a compassionate basis. It has been approved in several countries and is being provided on a compassionate basis in certain countries including Canada, Germany, Australia and Japan. The drug continues to demonstrate a significantly more benign side-effect profile compared to all the other EGFR-targeting antibodies and small molecules targeting the EGF tyrosine kinase signalling pathway. The absence of any cases of severe rash to date and the very rare instances of any of the other debilitating side effects holds the prospect for nimotuzumab to become best-in-class for this important family of EGFR-targeting agents.

Nimotuzumab global development programs

Nimotuzumab is licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB, S.A., the corporation representing the Centre for Molecular Immunology, which was responsible for the discovery and early development of this unique molecule. Nimotuzumab
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... 2014 Reports from CDC ... suffer from one or more chronic health conditions - ... can address some of these diseases, but may not ... sufferers face. While implanted nerve stimulation devices today offer ... nerve, which can induce side effects. , To ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... past week at the University of Chicagos Gleacher Center hosted ... was an opportunity to hear from four individuals, who have ... different cities, as a preview to what we might expect ... comes to Chicago in April, 2006. , ,Some Chicagoans have ...
... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
... The Orphan Drug Act of 1983 has created incentives for ... month, the Wall Street Journal examined the acts effects on ... , , Nearly half of all products produced by ... the largest biotech companies, Amgen and Genentech, were built on ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6FDA programs encourage and expedite drug development and approval 2FDA programs encourage and expedite drug development and approval 3FDA programs encourage and expedite drug development and approval 4
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... tragic losses to life, property, and the environment. But ... from done. Without vegetation, bare, burnt soil lies vulnerable ... regeneration. Now Assaf Inbar, a graduate student ... together with his supervisors Prof. Marcelo Sternberg of the ...
... University Hospital researchers have for the first time successfully ... is disturbed. The team headed by Prof. Christian Krner, ... Medicine, demonstrated that if female mice are given mannose ... pregnancy, their offspring will develop normally even if they ...
... continues its move toward renewable energy with an Office ... full production, with several systems already in the field. ... a portable, 300-watt, hybrid battery generator that uses the ... provide Marines with continuous power in the field. ...
Cached Biology News:Reclaiming the land after a forest fire 2Severe congenital disorder successfully treated in a mouse model for the first time 2Severe congenital disorder successfully treated in a mouse model for the first time 3Future is bright for ONR's lightweight, sun-powered generator 2
Ms anti-Cyclophilin D...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: